Morning Report | Hormuz reopening talks stall, crude risk premia keep inflation bid
$USO Hormuz talks stall, crude risk premium $BW guidance reset, stock rips $ASTS miss again, dilution overhang $NVDA courts $500B+ AI infrastructure capital $PFE vaccine order, HHS 90-day review
Market Pulse
U.S.-Iran War
4 events
Hormuz reopening talks stall and reparations demands harden, keeping crude risk premia elevated as markets weigh quick normalization versus prolonged constraints.
Latest Development
Negotiations to reopen the Strait of Hormuz hit an impasse, with Tehran setting conditions and President Trump signaling a shift toward escalating economic pressure while both sides raise compensation demands.
Oil jumped on fading near-term reopening hopes: WTI traded around $84.36/bbl (+2.7%) and Brent around $89.94/bbl (+2.53%), with Reuters citing Brent near $88 and up roughly 5% over two days.
The White House extended the Jones Act waiver another 90 days to mid-November, narrowed eligibility to certain energy-resource cargo, and added Pentagon case-by-case voyage vetting with Maritime Administration consultation.
DOE reported the SPR fell 6.1 million barrels w/w to 298.7 million, the lowest since 1983; reporting also cited a 172 million barrel release ordered in March and recent ~5% gains in Brent and WTI.
Market reaction
Crude repriced higher as talks stalled, with WTI near $84.36 (+2.7%) and Brent near $89.94 (+2.53%) early Tuesday after ~5% gains Monday; reporting also flagged higher yields alongside commodities (2Y ~4.253% +1 bp, 10Y ~4.72% +2 bps in Europe).
Our view
A headline-driven crude tape with an upside skew while Hormuz reopening remains unresolved and buffers look thinner. The key monitor is any concrete deal or operational evidence of sustained shipping-flow normalization that would quickly compress the risk premium.
What could change our view
Rapid, credible agreement enabling full Hormuz reopening and sustained shipping normalization.
Further escalation that tightens constraints and forces an inventory-driven demand adjustment.
Tickers: $USO, $CL=F
Earnings
4 events
Earnings tape shows sharp single-name dispersion as BW resets higher on guidance while ASTS slips on another miss and dilution concerns.
Latest Development
AST SpaceMobile posted Q2 revenue of $31.5M versus $35.18M consensus and an adjusted loss of -$0.77 versus -$0.26 expected, citing a $125.9M conversion loss tied to the BB7 incident.
Babcock & Wilcox beat with adjusted EPS $0.07 versus $0.03 and revenue $319.7M versus $197.0M, raised FY26 adjusted EBITDA to $80M–$105M, and added a $50M buyback plus a 2026 note redemption plan.
Trump Media reported Q2 revenue of about $1.7M and a $238.1M net loss, driven largely by more than $190M of non-cash digital-asset and equity mark-to-market losses; it also said Truth API has 10+ HFT clients at $60k–$100k per month.
Alcon lifted FY2026 profitability guidance after an expected ~$60M U.S. tariff refund and cut its annual tariff impact estimate to $40M–$90M; it raised margin-expansion and core EPS growth targets while keeping sales guidance unchanged.
Market reaction
BW was cited up ~40.5% premarket to about $12.48, while ASTS was cited down ~2.8% premarket to about $66.82.
Our view
Expect continued earnings-driven dispersion, with guidance raises and demonstrable profitability inflections rewarded while serial execution shortfalls and dilution optics cap high-volatility names. Next focus is cash conversion and working-capital discipline for BW, plus ASTS progress versus FY26 targets and the timing/recognition path for ALC’s tariff refund.
What could change our view
BW EBITDA upgrade fails to translate into sustainable cash generation and manageable working capital.
ASTS misses FY26 revenue range or dilution fears intensify after financing actions.
Tickers: $ASTS, $BW, $DJT, $ALC
AI
3 events
AI funding gears up as Nvidia courts $500B+ third-party infrastructure capital while Intel raises $20B equity and OpenAI’s $7B tender resets private pricing.
Latest Development
Nvidia signed non-binding MOUs with Apollo, Blackstone, BlackRock, Brookfield, Goldman Sachs and KKR to mobilize over $500B for data centers and Nvidia hardware via dedicated financing pools.
Intel upsized its common stock offering to $20B priced at $95, targeting about $19.7B net proceeds with closing Aug. 12 and a 30-day $2.25B greenshoe.
OpenAI completed a roughly $7B employee secondary tender at an $852B valuation, following a March $122B funding round and a June confidential SEC filing for a potential IPO.
Market reaction
Intel shares fell about 4% when the initially announced $15B offering was disclosed, highlighting dilution sensitivity ahead of the Aug. 12 close.
Our view
The AI buildout remains financeable, with capital-market and private-finance structures extending the runway even as dilution becomes a more visible funding tool. Next watchpoints are conversion of Nvidia’s MOUs into final agreements and Intel’s offering close/greenshoe, which will shape sentiment on capex sustainability.
What could change our view
Nvidia MOUs fail to convert or GPU obsolescence undermines collateral underwriting.
AI capex pressure worsens, forcing broader dilution and slowing customer hardware purchases.
Tickers: $NVDA, $INTC, $MSFT
Macro & Policy Digest
China teapot refiners may step up Iranian crude buying as Shandong stockpiles hit an eight-month low, tightening near-term seaborne balances into August.
Latest Development
Energy Aspects estimates Shandong crude inventories ended July near 360M barrels after an ~35M barrel monthly draw; with buffers depleted, teapot refiners are expected to raise Iranian crude purchases in August to sustain run-rates.
Our view
Bias to firmer near-term crude pricing as Chinese independent restocking draws incremental barrels from the spot market. Monitor August Iranian flows to Asia and whether teapot buying translates into broader seaborne tightening rather than simple replacement sourcing.
What could change our view
Teapot import restraint persists, limiting incremental buying despite low inventories.
Iranian barrels absorbed without tightening elsewhere, leaving net seaborne balances unchanged.
Tickers: $CL=F
Trump executive order seeks to narrow routine childhood vaccines, split MMR dosing, and forces a 90-day HHS review with DOJ scrutiny of state mandate exemptions.
Latest Development
An executive order directs “Gold Standard” childhood vaccine recommendations limiting routine coverage to 11 diseases, tiers some vaccines to high-risk only, calls to split MMR into separate shots, and orders an HHS reassessment within 90 days plus a DOJ review of state exemption practices.
Our view
Near term, treat this as a policy headline with limited immediate earnings impact for large vaccine makers while the HHS review process plays out. The key monitor is whether HHS codifies materially narrower routine recommendations and how implementation issues (including standalone MMR availability) are handled after the 90-day window.
What could change our view
HHS quickly formalizes reduced routine recommendations with enforceable operational guidance.
State mandate enforcement shifts materially, reducing pediatric vaccination uptake beyond targeted high-risk tiers.
Tickers: $PFE
Cyber stocks rip higher as Black Hat highlights AI-agent threats, fueling expectations for incremental AI-security spending and lifting sector leaders and ETFs.
Latest Development
CRWD and PANW jumped more than 5% to record highs after Black Hat discussions on AI-agent security; BTIG raised price targets to $237 and $380, with broad gains across RBRK, ZS, S, and SAIL.
Market reaction
Cyber ran as a basket: CRWD and PANW rose more than 5% to new highs, with RBRK up about 9%, ZS and Netskope about 5%, and SAIL and S about 4%.
Our view
We treat the AI-agent security narrative as a near-term tailwind for the cyber basket, favoring diversified exposure via HACK/BUG rather than single-name timing. Sustainability hinges on follow-through in spending commentary and whether the move broadens beyond the current risk-on factor bid around sector leaders.
What could change our view
Conference-driven enthusiasm fades and recent highs unwind without new budget signals.
Leaders decouple as rotation hits high-multiple cyber names despite sector theme.
Tickers: $HACK
China autos show demand split as July passenger car sales fall sharply while exports surge, reinforcing weak domestic consumption and intensifying global price competition.
Latest Development
CPCA said July passenger car sales fell 21.1% y/y to 1.47m (10th straight decline) as exports rose 88.2% to 923k; EV/PHEV exports +147.8% while domestic EV/PHEV sales -3.9%.
Our view
The auto data keep us cautious on China domestic-demand exposure, with exports cushioning activity but signaling continued discounting and margin pressure. Monitor for stabilization in domestic EV/PHEV sell-through versus deeper promotions and an accelerated export push that amplifies global pricing competition for automakers.
What could change our view
Domestic passenger car demand rebounds, reducing discounting and improving margins.
Export growth slows materially, exposing weaker domestic consumption in activity data.
Tickers: $FXI
Company Events
Archer jumps on Boeing asset sale, gaining autonomy, air-taxi traffic management and drone capabilities while Boeing takes a 19.75% equity stake plus options.
Latest Development
Boeing is selling Wisk Aero, SkyGrid and Insitu to Archer; consideration is a 19.75% Archer Class A stake plus four-year options, with no disclosed cash, valuation or closing timetable.
Market reaction
Archer shares gained nearly 12% Monday as investors treated the package as a technology expansion (Wisk autonomy and SkyGrid) plus a defense adjacency via Insitu.
Our view
ACHR sentiment stays supported near term as the Boeing-sourced asset package broadens the platform narrative beyond a pure commercial eVTOL launch story. The key monitor is deal structure detail—especially cash needs, valuation, and closing timetable—as filings emerge.
What could change our view
Deal terms imply meaningful cash outlay or dilution for Archer.
Closing timetable slips or regulatory/contract frictions disrupt asset transfer.
Tickers: $ACHR
SpaceX pops back above its $135 IPO level on first post-IPO revenue beat, while a massive lockup release threatens near-term tape volatility.
Latest Development
SpaceX shares rose about 4% Monday to close back above $135 after Q2 revenue beat ($7.81B vs $6.93B est.) and the CFO reiterated a $100B ARR by year-end target, with >911M shares newly tradable post-lockup.
Market reaction
SpaceX rallied ~4% Monday and reclaimed the $135 IPO price for the first time since July 15 after the Q2 revenue beat, following a recent low close of $108.27 amid post-IPO volatility.
Our view
The fundamental beat supports a bid, but near-term performance is dominated by incremental float and positioning rather than narrative upgrades. Monitor post-lockup supply absorption and whether the $135 level holds as trading digests newly tradable shares.
What could change our view
Lockup-driven supply overwhelms demand, sending shares back below the $135 IPO level.
Failure to hit key Starship milestones undermines confidence in the $100B ARR trajectory.
Tickers: $ARKX
Lilly’s oral GLP-1 Foundayo wins U.K. MHRA authorization, with NHS adoption now hinging on NICE cost-effectiveness and access terms.
Latest Development
The U.K. MHRA authorized Eli Lilly’s orforglipron (Foundayo) for prescription weight management and type 2 diabetes, while broad NHS reimbursement and uptake awaits a separate NICE technology appraisal and negotiated access terms.
Our view
The MHRA approval is a positive step, but near-term commercial impact in the U.K. remains gated by NICE and reimbursement outcomes. The key monitor is the timing and scope of NICE’s appraisal, including any pricing or managed-access conditions that shape covered population.
What could change our view
NICE deems Foundayo not cost-effective or restricts the eligible covered population.
Access terms require deeper concessions, delaying uptake and weakening the launch profile.
Tickers: $LLY
Go deeper -
For intraday developments, follow our Midday posts.
For the close, the wrap, and next-day trade ideas, read the Evening Memo.
For deeper work, Forward Valuation covers multi-week single-name setups (paid subscribers only).
Deep Dive is where we publish our full thematic research for paid subscribers.
Informational only; not investment advice. Sources deemed reliable.